About Xenon Pharmaceuticals Inc.
https://www.xenon-pharma.comXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.
CEO
Ian C. Mortimer CPA,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 97
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Needham
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Goldman Sachs
Buy
RBC Capital
Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FMR LLC
Shares:8.92M
Value:$370.85M
AVORO CAPITAL ADVISORS LLC
Shares:5.4M
Value:$224.53M
BLACKROCK, INC.
Shares:4.77M
Value:$198.38M
Summary
Showing Top 3 of 245
About Xenon Pharmaceuticals Inc.
https://www.xenon-pharma.comXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $19.28M ▼ | $-90.9M ▼ | 0% | $-1.15 ▼ | $-89.58M ▲ |
| Q2-2025 | $0 ▼ | $93.6M ▲ | $-84.71M ▼ | 0% ▲ | $-1.07 ▼ | $-93.6M ▼ |
| Q1-2025 | $7.5M ▲ | $80.24M ▲ | $-65.05M ▲ | -867.29% ▼ | $-0.83 ▲ | $-72.08M ▲ |
| Q4-2024 | $0 | $77.48M ▲ | $-65.69M ▼ | 0% | $-0.84 ▼ | $-76.84M ▼ |
| Q3-2024 | $0 | $73.68M | $-62.79M | 0% | $-0.81 | $-72.98M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $462.27M ▼ | $607.84M ▼ | $48.33M ▲ | $559.51M ▼ |
| Q2-2025 | $487.55M ▼ | $674.28M ▼ | $40.3M ▲ | $633.98M ▼ |
| Q1-2025 | $549.63M ▼ | $743.28M ▼ | $39.32M ▼ | $703.96M ▼ |
| Q4-2024 | $626.9M ▼ | $798.14M ▼ | $43.24M ▲ | $754.9M ▼ |
| Q3-2024 | $654.01M | $835.9M | $38.09M | $797.81M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-90.9M ▼ | $-71.75M ▼ | $38.53M ▼ | $2.36M ▲ | $-30.87M ▼ | $-72.03M ▼ |
| Q2-2025 | $-84.71M ▼ | $-64.23M ▼ | $82.26M ▲ | $65K ▼ | $18.72M ▲ | $-64.39M ▼ |
| Q1-2025 | $-65.05M ▲ | $-61.65M ▼ | $34.51M ▼ | $1.15M ▼ | $-26.05M ▼ | $-61.7M ▼ |
| Q4-2024 | $-65.69M ▼ | $-54.38M ▼ | $98.5M ▲ | $12.13M ▲ | $55.09M ▲ | $-55.17M ▼ |
| Q3-2024 | $-62.79M | $-49.66M | $498K | $0 | $-49.11M | $-50.26M |
Revenue by Products
| Product | Q4-2021 | Q1-2022 | Q2-2022 | Q3-2022 |
|---|---|---|---|---|
 License And Service | $10.00M ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
CEO
Ian C. Mortimer CPA,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 97
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Needham
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Goldman Sachs
Buy
RBC Capital
Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FMR LLC
Shares:8.92M
Value:$370.85M
AVORO CAPITAL ADVISORS LLC
Shares:5.4M
Value:$224.53M
BLACKROCK, INC.
Shares:4.77M
Value:$198.38M
Summary
Showing Top 3 of 245